1. Home
  2. THAR vs UCL Comparison

THAR vs UCL Comparison

Compare THAR & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • UCL
  • Stock Information
  • Founded
  • THAR 2017
  • UCL 2014
  • Country
  • THAR United States
  • UCL Hong Kong
  • Employees
  • THAR N/A
  • UCL N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • UCL Telecommunications Equipment
  • Sector
  • THAR Health Care
  • UCL Consumer Discretionary
  • Exchange
  • THAR Nasdaq
  • UCL Nasdaq
  • Market Cap
  • THAR 85.9M
  • UCL 70.7M
  • IPO Year
  • THAR 2022
  • UCL 2020
  • Fundamental
  • Price
  • THAR $2.54
  • UCL $2.00
  • Analyst Decision
  • THAR Strong Buy
  • UCL
  • Analyst Count
  • THAR 1
  • UCL 0
  • Target Price
  • THAR $17.00
  • UCL N/A
  • AVG Volume (30 Days)
  • THAR 3.5M
  • UCL 13.2K
  • Earning Date
  • THAR 11-12-2025
  • UCL 11-12-2025
  • Dividend Yield
  • THAR N/A
  • UCL N/A
  • EPS Growth
  • THAR N/A
  • UCL 8.06
  • EPS
  • THAR N/A
  • UCL 0.12
  • Revenue
  • THAR N/A
  • UCL $85,239,000.00
  • Revenue This Year
  • THAR N/A
  • UCL N/A
  • Revenue Next Year
  • THAR N/A
  • UCL $20.86
  • P/E Ratio
  • THAR N/A
  • UCL $15.63
  • Revenue Growth
  • THAR N/A
  • UCL N/A
  • 52 Week Low
  • THAR $0.95
  • UCL $0.80
  • 52 Week High
  • THAR $9.08
  • UCL $4.19
  • Technical
  • Relative Strength Index (RSI)
  • THAR 40.23
  • UCL 36.11
  • Support Level
  • THAR $2.18
  • UCL $2.07
  • Resistance Level
  • THAR $2.55
  • UCL $2.63
  • Average True Range (ATR)
  • THAR 0.42
  • UCL 0.13
  • MACD
  • THAR -0.10
  • UCL -0.02
  • Stochastic Oscillator
  • THAR 10.34
  • UCL 22.22

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

Share on Social Networks: